INS and metabolic dysfunction-associated steatohepatitis: For example, nonalcoholic steatohepatitis patients treated with high-dose UDCA experienced significant reductions in serum glucose, glycosylated hemoglobin, and serum insulin levels (Ratziu et al. 2011).